Paradigm Biopharmaceuticals Enters Voluntary Administration

The formal appointment of voluntary administrators is a new, directly reported financial-distress action, not a market-price observation. It materially changes Paradigm Biopharmaceuticals’ financing, operating, clinical-program and ASX-trading prospects, while the proposed deed of company arrangement and expected minimum eight-week review create clear forward implications. The appointment date of 29 September 2026 is explicitly supported, but no precise event time is provided; the timestamp is therefore normalized to the start of that UTC date rather than using the source-publication time. The process is ongoing. Importance is high because this is a company-specific administration and trading suspension, while surprise is meaningful but not maximal because it followed a disclosed Phase 3 setback and funding review. The prior decision to create a new financial-distress event is retained. Only PAR is approved as a stakeholder because the supplied competitor and clinical-research-provider impacts are indirect, speculative, or lack event-specific commercial evidence.